An Organoid-on-chips Technique Based on Biopsy Samples and Its Efficacy in Predicting the Response to HAI in HCC

Prior treatment

• Patients who underwent chemotherapy, immunotherapy, antitumor vaccines or other antitumor drugs within 2 months.

Other illness

• Severe heart and lung dysfunction。
• Irreversible bleeding tendency.
• Patients who have had or are currently suffering from other malignant tumors (except for cured basal or squamous cell skin cancer or cervical in situ cancer);
• with grade II or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias, and grade III-IV heart failure.
• Uncontrollable systemic infection.

Lab values

• White blood cell count \<2.5×10\^9/L or platelet count \<50×10\^9/L.
• Renal dysfunction (creatinine\>2mg/L).
• Liver dysfunction (Child-Pugh≥9 points or bilirubin\>75μmol/L).
• Poor coagulation function INR\>1.5, or undergoing anticoagulant therapy or known bleeding disorders.

Other

• There are obvious infectious lesions or important structures that cannot be avoided along the puncture path.
• Complications or social environment that may cause subjects to fail to follow the study plan or even endanger patient safety.
• Participating in another therapeutic clinical trial at the same time.
• Pregnant or lactating women.

• Patients who need to undergo biopsy for clinically and/or pathologically diagnosed (suspected) with malignant solid tumors including breast cancer, lung cancer, liver cancer, bile duct cancer or pancreatic cancer, et.al.
• ECOG score ≤ 2.
• Age between 18-75 years old.
  • (5) Understand and sign the informed consent form.
• Age 18-75 years old.
• Hepatocellular carcinoma (HCC) confirmed by pathological histology BCLC stage C or CNLC stage IIIA and treated by hepatic artery infusion with mFOLFOX6.
• At least one lesion that can be evaluated by RECIST 1.1 criteria; lesions that have undergone local treatment (TACE/TAE, ablation, radiotherapy) should not be included (unless there is progression at baseline assessment at entry, in which case it should be classified as non-target lesions/unmeasurable lesions).
• Liver function Child-Pugh A or B level (≤8 points).
• ECOG PS ≤ 2 points.
• Expected survival time \> 3 months.
• Understand and sign the informed consent form.